Important Safety Information
Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (Advanced HR+ BC)
AFINITOR is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in
combination with exemestane after failure of treatment with letrozole or anastrozole.
Advanced Neuroendocrine Tumors of Pancreatic Origin (advanced PNET)
AFINITOR is indicated for the treatment of adults with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced, or metastatic disease. AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors.
Advanced Renal Cell Carcinoma (RCC)
AFINITOR is indicated for the treatment of adults with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.